Rosenberg, J. E., Sharma, P., de Braud, F. G. M., Basso, U., Calvo, E., Bono, P., … Siefker-Radtke, A. O. (2018). Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032. In Ann Oncol (Vol. 29 Suppl 8, p. viii725). England. https://doi.org/10.1093/annonc/mdy424.038

Rosenberg, J. E., P. Sharma, F. G. M. de Braud, U. Basso, E. Calvo, P. Bono, M. Morse, et al. “Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032.” In Ann Oncol, 29 Suppl 8:viii725, 2018. https://doi.org/10.1093/annonc/mdy424.038.

Rosenberg JE, Sharma P, de Braud FGM, Basso U, Calvo E, Bono P, et al. Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032. In: Ann Oncol. 2018. p. viii725.

Rosenberg, J. E., et al. “Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032.” Ann Oncol, vol. 29 Suppl 8, 2018, p. viii725. Pubmed, doi:10.1093/annonc/mdy424.038.

Rosenberg JE, Sharma P, de Braud FGM, Basso U, Calvo E, Bono P, Morse M, Ascierto PA, Lopez-Martin JA, Brossart P, Rohrberg KS, Reguart N, Lin WH, Meadows-Shropshire S, Saci A, Callahan M, Siefker-Radtke AO. Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032. Ann Oncol. 2018. p. viii725.